Physician profile
Robert C Scanlon
NPI 1013915792
$464.68
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $196.71 | 2019 | |
| Boston Scientific Corporation | $98.19 | 2019 | |
| Amgen INC. | $51.31 | 2019 | |
| Abbvie INC. | $29.89 | 2019 | |
| Blue Earth Diagnostics | $19.02 | 2019 | |
| Dendreon Pharmaceuticals LLC | $15.48 | 2019 | |
| Travere Therapeutics, INC. | $15.15 | 2019 | |
| Janssen Biotech, INC. | $14.42 | 2019 | |
| Olympus America INC. | $13.61 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.